文献速递产科母胎医学

胎盘、胎儿及母体心血管标志物对疑似或确诊子痫前期妇女不良结局的预测作用

Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

这项前瞻性预后准确性研究纳入126例疑似或确诊子痫前期孕妇,评估胎盘、胎儿及母体心血管标志物预测不良围产及母体结局的能力。sFlt-1/PlGF比值预测不良围产结局表现良好(AUC 0.87),但所有标志物预测不良母体结局均表现不佳(sFlt-1与sFlt-1/PlGF比值AUC均为0.69)。在sFlt-1/PlGF比值基础上加入心血管、胎儿或其他胎盘指标未改善预测。

要点

  • sFlt-1/PlGF比值预测不良围产结局AUC 0.87(95%CI 0.81-0.93),为最佳单一标志物。
  • 所有标志物预测不良母体结局均表现不佳,sFlt-1与sFlt-1/PlGF比值AUC均为0.69。
  • 在sFlt-1/PlGF比值基础上加入心血管、胎儿或其他胎盘指标未改善预测。

核心结论

  • sFlt-1/PlGF比值在疑似或确诊子痫前期妇女中能较好预测不良围产结局,但对不良母体结局预测能力差。
  • 在模型中加用心血管或胎儿指标不太可能改善sFlt-1/PlGF比值的预后效能。

研究设计与样本

  • 前瞻性预后准确性研究,纳入126例疑似(n=31)或确诊(n=95)子痫前期孕妇,中位孕周33.9周(四分位距30.9-36.3周)。
  • 检测母体血流动力学指标、平均动脉压、增强指数、眼动脉收缩期峰值流速比值、子宫动脉搏动指数、胎儿生物测量与多普勒参数、sFlt-1及PlGF。
  • 采用受试者工作特征曲线分析评估各标志物单独或联合预测不良围产及母体结局的效能。

主要发现

  • 发生不良围产结局者较未发生者中位UtA-PI更高(1.3 vs 0.8;P<0.001),眼动脉PSV比值更高(0.8 vs 0.7;P=0.01),脐动脉PI百分位更高(82.0 vs 68.5;P<0.01)。
  • 发生不良围产结局者中位估计胎儿体重百分位更低(4.0 vs 43.0;P<0.001),腹围百分位更低(4.0 vs 63.0;P<0.001),大脑中动脉PI百分位更低(28.0 vs 58.5;P<0.001),脑胎盘比值百分位更低(18.0 vs 46.5;P<0.001)。
  • 发生不良围产结局者中位sFlt-1更高(8208.0 pg/mL vs 4508.0 pg/mL;P<0.001),PlGF更低(27.2 pg/mL vs 76.3 pg/mL;P<0.001),sFlt-1/PlGF比值更高(445.4 vs 74.4;P<0.001)。
  • 预测不良围产结局最佳单一标志物为sFlt-1/PlGF比值(AUC 0.87(95%CI 0.81-0.93)),其次为估计胎儿体重(AUC 0.81(95%CI 0.73-0.89))。
  • 发生不良母体结局者中位sFlt-1更高(7471.0 pg/mL vs 5131.0 pg/mL;P<0.001),sFlt-1/PlGF比值更高(204.3 vs 93.3;P<0.001),PlGF更低(37.0 pg/mL vs 66.1 pg/mL;P=0.01),估计胎儿体重百分位更低(16.5 vs 37.0;P=0.04)。

关键数值与推荐

  • 不良母体结局定义为以下一项或多项:严重高血压、入住重症监护室、子痫、胎盘早剥、HELLP综合征、弥散性血管内凝血、血小板<100×10^9/L、肌酐>90 μmol/L、丙氨酸氨基转移酶>100 U/L。
  • 不良围产结局定义为以下一项或多项:孕34+0周及以前早产、新生儿重症监护室入住>48小时、呼吸窘迫综合征、脑室内出血、缺氧缺血性脑病、坏死性小肠结肠炎、早产儿视网膜病变、确诊胎儿感染。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the performance of placental, fetal and maternal cardiovascular markers in the prediction of adverse perinatal and maternal outcomes in women with suspected or confirmed pre-eclampsia. METHODS: This was a prospective prognostic accuracy study of women with suspected or confirmed pre-eclampsia who underwent a series of investigations to measure maternal hemodynamic indices, mean arterial pressure, augmentation index, ophthalmic artery peak systolic velocity (PSV) ratio, uterine artery pulsatility index (UtA-PI), fetal biometric and Doppler parameters, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF). The performance of these markers, individually or in combination, in predicting adverse perinatal and maternal outcomes was then assessed using receiver-operating-characteristics (ROC)-curve analysis. Adverse maternal outcome was defined as one or more of severe hypertension, admission to the intensive care unit, eclampsia, placental abruption, HELLP syndrome, disseminated intravascular coagulation, platelets < 100 × 109 /L, creatinine > 90 μmol/L and alanine aminotransferase > 100 U/L. Adverse perinatal outcome was defined as one or more of preterm birth at or before 34 + 0 weeks, neonatal intensive care unit admission for > 48 h, respiratory distress syndrome, intraventricular hemorrhage, hypoxic ischemic encephalopathy, necrotizing enterocolitis, retinopathy of prematurity and confirmed fetal infection. RESULTS: We recruited 126 women with suspected (n = 31) or confirmed (n = 95) pre-eclampsia at a median gestational age of 33.9 weeks (interquartile range, 30.9-36.3 weeks). Pregnancies with adverse perinatal outcome compared to those without had a higher median UtA-PI (1.3 vs 0.8; P < 0.001), ophthalmic artery PSV ratio (0.8 vs 0.7; P = 0.01) and umbilical artery PI percentile (82.0 vs 68.5; P < 0.01) and lower median estimated fetal weight percentile (4.0 vs 43.0; P < 0.001), abdominal circumference percentile (4.0 vs 63.0; P < 0.001), middle cerebral artery PI percentile (28.0 vs 58.5; P < 0.001) and cerebroplacental ratio percentile (18.0 vs 46.5; P < 0.001). Pregnancies with adverse perinatal outcome also had a higher median sFlt-1 (8208.0 pg/mL vs 4508.0 pg/mL; P < 0.001), lower PlGF (27.2 pg/mL vs 76.3 pg/mL; P < 0.001) and a higher sFlt-1/PlGF ratio (445.4 vs 74.4; P < 0.001). The best performing individual marker for predicting adverse perinatal outcome was the sFlt-1/PlGF ratio (area under the ROC curve (AUC), 0.87 (95% CI, 0.81-0.93)), followed by estimated fetal weight (AUC, 0.81 (95% CI, 0.73-0.89)). Women who experienced adverse maternal outcome had a higher median sFlt-1 level (7471.0 pg/mL vs 5131.0 pg/mL; P < 0.001) and sFlt-1/PlGF ratio (204.3 vs 93.3; P < 0.001) and a lower PlGF level (37.0 pg/mL vs 66.1 pg/mL; P = 0.01) and estimated fetal weight percentile (16.5 vs 37.0; P = 0.04). All markers performed poorly in predicting adverse maternal outcome, with sFlt-1 (AUC, 0.69 (95% CI, 0.60-0.79)) and sFlt-1/PlGF ratio (AUC, 0.69 (95% CI, 0.59-0.78)) demonstrating the best individual performance. The addition of cardiovascular, fetal or other placental indices to the sFlt-1/PlGF ratio did not improve the prediction of adverse maternal or perinatal outcomes. CONCLUSIONS: The sFlt-1/PlGF ratio performs well in predicting adverse perinatal outcomes but is a poor predictor of adverse maternal outcomes in women with suspected or diagnosed pre-eclampsia. The addition of cardiovascular or fetal indices to the model is unlikely to improve the prognostic performance of the sFlt-1/PlGF ratio. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Reddy M, Palmer K, Rolnik DL, et al. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2022. PMID: 34985800. doi:10.1002/uog.24851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。